The Journal of Urology
Volume 178, Issue 5 , Pages 2029-2034, November 2007

Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical Study

  • Philip E.V. van Kerrebroeck

      Affiliations

    • Academisch Ziekenhuis Maastricht, Maastricht, The Netherlands
    • Nothing to disclose.
    • Corresponding Author InformationCorrespondence: Department of Urology, Academisch Ziekenhuis Maastricht, Postbus 5800, 6202 AZ Maastricht, The Netherlands (telephone: +31 43 387 7258; FAX: +31 43 387 72).
  • ,
  • Anco C. van Voskuilen

      Affiliations

    • Academisch Ziekenhuis Maastricht, Maastricht, The Netherlands
    • Nothing to disclose.
  • ,
  • John P.F.A. Heesakkers

      Affiliations

    • Academisch Ziekenhuis Radboud, Nijmegen, The Netherlands
    • Financial interest and/or other relationship with Medtronic.
  • ,
  • August A.B. Lycklama á Nijholt

      Affiliations

    • Academisch Ziekenhuis Leiden, Leiden, The Netherlands
    • Nothing to disclose.
  • ,
  • Steven Siegel

      Affiliations

    • Metropolitan Urologic Specialists, St. Paul, Minnesota
    • Financial interest and/or other relationship with Medtronic, AMS, Astellas, Pfizer, Advanced Bionics, Uroplasty and Uromedica.
  • ,
  • U. Jonas

      Affiliations

    • Hannover Medical School, Hannover, Germany
    • Financial interest and/or other relationship with Pfizer, J&J, Novartis, UCB, Bayer and Boehringer.
  • ,
  • Clare J. Fowler

      Affiliations

    • National Hospital for Neurology and Neurosurgery, London, United Kingdom
    • Financial interest and/or other relationship with Medtronic, Allergan and Pfizer.
  • ,
  • Magnus Fall

      Affiliations

    • Sahlgrenska Hospital, University of Gothenberg, Gothenberg, Sweden
    • Financial interest and/or other relationship with Medtronics Inc., Astellas Pharma, BioXell SpA and Pfizer.
  • ,
  • Jerzy B. Gajewski

      Affiliations

    • Queen Elizabeth II Health Science Center, Halifax, Nova Scotia, Canada
    • Financial interest and/or other relationship with Pfizer Canada, Alza, Allergan, Solvay Pharma Inc., Bayer, Lilly Icos, Sanofi-Synthelabo, Janssen-Ortho Inc., Astellas, Medtronic and Purdue Pharma.
  • ,
  • Magdy M. Hassouna

      Affiliations

    • Toronto Hospital, Toronto, Ontario, Canada
    • Nothing to disclose.
  • ,
  • Francesco Cappellano

      Affiliations

    • Policlinico Multimedica, Milano, Italy
    • Nothing to disclose.
  • ,
  • Mostafa M. Elhilali

      Affiliations

    • Royal Victoria Hospital, Montreal, Québec, Canada
    • Financial interest and/or other relationship with Novartis, Negma Lerad, Sanofi-Synthelabo, Pfizer, Laserscope, QLT and Lumenis.
  • ,
  • Douglas F. Milam

      Affiliations

    • Vanderbilt University, Nashville, Tennessee
    • Financial interest and/or other relationship with Medtronic, AMS, Pfizer and Alza.
  • ,
  • Anurag K. Das

      Affiliations

    • Albany Medical College, Albany, New York
    • Financial interest and/or other relationship with Boehringer-Ingelheim, Astellas, Schwarz, Glaxo, Eli Lilly, Boston Scientific and Novartis.
  • ,
  • H.E. Dijkema

      Affiliations

    • Twenteborg Ziekenhuis, Almelo, The Netherlands
    • Nothing to disclose.
  • ,
  • Ubi van den Hombergh

      Affiliations

    • Medtronic, Medtronic Sarl, Tolochenaz, Switzerland
    • Nothing to disclose.

Received 13 March 2007 published online 17 September 2007.

Purpose

This 5-year, prospective, multicenter trial evaluated the long-term safety and efficacy of sacral neuromodulation in patients with refractory urge incontinence, urgency frequency and retention.

Materials and Methods

A total of 17 centers worldwide enrolled 163 patients (87% female). Following test stimulation 11 patients declined implantation and 152 underwent implantation using InterStim®. Of those treated with implantation 96 (63.2%) had urge incontinence, 25 (16.4%) had urgency frequency and 31 (20.4%) had retention. Voiding diaries were collected annually for 5 years. Clinical success was defined as 50% or greater improvement from baseline in primary voiding diary variable(s).

Results

Data for all implanted cases were reported. For patients with urge incontinence mean leaking episodes per day decreased from 9.6 ± 6.0 to 3.9 ± 4.0 at 5 years. For patients with urgency frequency mean voids per day decreased from 19.3 ± 7.0 to 14.8 ± 7.6, and mean volume voided per void increased from 92.3 ± 52.8 to 165.2 ± 147.7 ml. For patients with retention the mean volume per catheterization decreased from 379.9 ± 183.8 to 109.2 ± 184.3 ml, and the mean number of catheterizations decreased from 5.3 ± 2.8 to 1.9 ± 2.8. All changes were statistically significant (p <0.001). No life threatening or irreversible adverse events occurred. In 102 patients 279 device or therapy related adverse events were observed. At 5 years after implantation 68% of patients with urge incontinence, 56% with urgency frequency and 71% with retention had successful outcomes.

Conclusions

This long-term study demonstrates that InterStim therapy is safe and effective for restoring voiding in appropriately selected cases refractory to other forms of treatment.

Key Words: electric stimulation therapy, urination disorders, urinary bladder

Abbreviations and Acronyms: AE, adverse event, FDA, Food and Drug Administration, INS, implantable neurostimulator, PAS, post approval study, PNE, percutaneous nerve evaluation, SNM, sacral neuromodulation, UF, urgency frequency, UI, urge incontinence

 

 Study received approval from all ethical committees.

 See Editorial on page 1844. For another article on a related topic see page 2203.

 Editor’s Note: This article is the third of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2226 and 2227.

PII: S0022-5347(07)01768-5

doi:10.1016/j.juro.2007.07.032

Refers to article:

  • Neuromodulation and the Urinary Tract—Are We Over the Rainbow or Have We Simply Stepped Through the Looking Glass? , 14 September 2007

    Roger Dmochowski
    The Journal of Urology November 2007 (Vol. 178, Issue 5, Pages 1844-1845)

  • Aldose Reductase Inhibitor ONO-2235 Restores the Alterations of Bladder Nerve Growth Factor and Neurotrophin Receptor p75 Genetic Expression in Streptozotocin Induced Diabetic Rats , 17 September 2007

    Yat-Ching Tong, Juei-Tang Cheng
    The Journal of Urology November 2007 (Vol. 178, Issue 5, Pages 2203-2207)

The Journal of Urology
Volume 178, Issue 5 , Pages 2029-2034, November 2007